EXHIBIT 10.2 INTELLECTUAL PROPERTY TRANSFER AND LICENSE AGREEMENT This Intellectual Property Transfer and License Agreement (this "Agreement") is made by and between Johnson & Johnson Consumer Companies, Inc., a New Jersey corporation having an...Transfer and License Agreement • April 28th, 2004 • Barrier Therapeutics Inc • Pharmaceutical preparations • New York
24 APRIL 2007Transfer and License Agreement • August 9th, 2007 • Isotis Inc • Services-commercial physical & biological research
INTELLECTUAL PROPERTY TRANSFER AND LICENSE AGREEMENT BETWEEN NXP B.V. AND NXP HOLDING 1 B.V. DATED AS OF FEBRUARY 7, 2010Transfer and License Agreement • July 16th, 2010 • Trident Microsystems Inc • Semiconductors & related devices • New York
This Intellectual Property Transfer and License Agreement (“Agreement”) is made and entered into, as of February 7, 2010 (the “Closing Date”), by and between NXP B.V., a Dutch besloten venootshap (“NXP”), and NXP Holding 1 B.V., a Dutch besloten venootshap (“Dutch Newco”).
EX-10.5 2 d910116dex105.htm EX-10.5 EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. ASSET TRANSFER...Transfer and License Agreement • May 5th, 2020 • Delaware
This ASSET TRANSFER AND LICENSE AGREEMENT (the “Agreement”) is dated as of April 10, 2015 (the “Effective Date”) between Alkermes Pharma Ireland Limited, a private limited company incorporated in Ireland (registered number 448848) whose registered address is Connaught House, 1 Burlington Road, Dublin 4, Ireland (“APIL”), and DV Technology LLC, a Delaware limited liability company whose registered address is c/o Corporation Trust Center, 1209 Orange Street, Wilmington, Delaware 19801, USA (“Purchaser,” and Purchaser shall include, after the Effective Date, any entity possessing the obligations of Purchaser set forth in this Agreement).
CONFIDENTIAL TREATMENT REQUESTED - CONFIDENTIAL PORTIONS OF THIS DOCUMENT HAVE BEEN REDACTED AND HAVE BEEN SEPARATELY FILED WITH THE COMMISSION. *** INDICATES CONFIDENTIAL MATERIAL REDACTED AND SEPARATELY FILED WITH THE COMMISSION INTELLECTUAL...Transfer and License Agreement • August 4th, 2010 • NXP Semiconductors N.V. • Semiconductors & related devices
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***] HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. ASSET TRANSFER AND LICENSE AGREEMENTTransfer and License Agreement • October 7th, 2019 • Baudax Bio, Inc. • Services-misc health & allied services, nec • Delaware
This ASSET TRANSFER AND LICENSE AGREEMENT (the “Agreement”) is dated as of April 10, 2015 (the “Effective Date”) between Alkermes Pharma Ireland Limited, a private limited company incorporated in Ireland (registered number 448848) whose registered address is Connaught House, 1 Burlington Road, Dublin 4, Ireland (“APIL”), and DV Technology LLC, a Delaware limited liability company whose registered address is c/o Corporation Trust Center, 1209 Orange Street, Wilmington, Delaware 19801, USA (“Purchaser,” and Purchaser shall include, after the Effective Date, any entity possessing the obligations of Purchaser set forth in this Agreement).
CONFIDENTIAL TREATMENT REQUESTED - CONFIDENTIAL PORTIONS OF THIS DOCUMENT HAVE BEEN REDACTED AND HAVE BEEN SEPARATELY FILED WITH THE COMMISSION *** INDICATES CONFIDENTIAL MATERIAL REDACTED AND SEPARATELY FILED WITH THE COMMISSION INTELLECTUAL PROPERTY...Transfer and License Agreement • June 30th, 2010 • NXP Semiconductors N.V. • Semiconductors & related devices
EX-10.26 5 dex1026.htm TECHNOLOGY TRANSFER AND LICENSE AGREEMENT DATED AS OF DECEMBER 29, 2009 STAIRMASTER TECHNOLOGY TRANSFER AND LICENSE AGREEMENTTransfer and License Agreement • May 5th, 2020
THIS STAIRMASTER TECHNOLOGY TRANSFER AND LICENSE AGREEMENT (hereinafter “Stairmaster Technology Agreement” or “Agreement”) relates to technology connected with the Nautilus Stairmaster business and is effective as of the date of signing by the last of the parties to sign below and is by and between Xiamen World Gear Sports Goods Co., Ltd. a corporation organized under the laws of the People’s Republic of China (“Buyer”), having a place of business at 27-29 North 2nd Road, Xinglin, Jimei District, Xiamen City, Fujian Province, People’s Republic of China and Nautilus, Inc. (“Nautilus”), a Washington corporation, having a place of business at 16400 SE Nautilus Drive, Vancouver, WA. 98683. Buyer and Nautilus are referred to collectively herein as the “Parties”. This Stairmaster Technology Agreement is an exhibit to a Stairmaster Asset Purchase Agreement relating to the Nautilus Stairmaster business entered into on the same date between Buyer and Nautilus. The parties agree as follows:
Amendment 2 to Asset Transfer and License AgreementTransfer and License Agreement • May 22nd, 2017 • Avenue Therapeutics, Inc. • Pharmaceutical preparations
This second amendment ("Amendment 2") to the Asset Transfer and License Agreement by and between Revogenex Ireland Limited, an Irish limited company ("Revogenex"), and Fortress Biotech, Inc. (f/k/a Coronado Biosciences, Inc.), a Delaware corporation ("Fortress") dated as of February 17, 2015 (the "Agreement"), is entered into as of May 4th, 2017. Fortress and Revogenex are both referred to herein as "Parties" or each individually, as a "Party."
ContractTransfer and License Agreement • May 5th, 2020 • Delaware
EX-10.91 2 exhibit_10-91.htm EXHIBIT 10.91 [***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT EXHIBIT 10.91 SECOND AMENDED AND RESTATED TECHNOLOGY TRANSFER AND LICENSE AGREEMENT This SECOND AMENDED AND RESTATED TECHNOLOGY TRANSFER AND LICENSE AGREEMENT (this “Agreement”), is made and entered into as of this 9th day of April, 2010 (“Amendment Date”), by and between Micron Technology, Inc, a Delaware corporation (“Micron”), and Nanya Technology Corporation (南亞科技股份有限公司), a company incorporated under the laws of the Republic of China (“NTC”). (Micron and NTC are referred to in this Agreement individually as a “Party” and collectively as the “Parties”). RECITALS A. Micron currently designs and manufactures Stack DRAM Products (as defined herein) and develops Process Technology (as defined herein) therefor. NTC and Micron desire to engage in joint development and/or optimization of Pro
EX-10.2 5 dex102.htm INTELLECTUAL PROPERTY TRANSFER AND LICENSE AGREEMENT DATED AS OF NOV 16, 2009 EXECUTION VERSIONTransfer and License Agreement • May 5th, 2020 • New York
CONFIDENTIAL TREATMENT REQUESTED - CONFIDENTIAL PORTIONS OF THIS DOCUMENT HAVE BEEN REDACTED AND HAVE BEEN SEPARATELY FILED WITH THE COMMISSION.
AMENDMENT NO. 2 TO PLATFORM TECHNOLOGY TRANSFER AND LICENSE AGREEMENTTransfer and License Agreement • May 8th, 2019 • Codexis Inc • Industrial organic chemicals
This AMENDMENT NO. 2 TO PLATFORM TECHNOLOGY TRANSFER AND LICENSE AGREEMENT (“Amendment No. 2”) is effective as of January 1, 2019 (the “Amendment No. 2 Effective Date”) by and between CODEXIS, INC., a Delaware corporation, having a place of business at 200 Penobscot Drive, Redwood City, CA 94063 (“CODEXIS”) and MERCK SHARP AND DOHME CORP., having a place of business at One Merck Drive, Whitehouse Station, NJ 08889-0100. (“MERCK”).
AMENDMENT NO. 1 TO JPPLP INTELLECTUAL PROPERTY TRANSFER AND LICENSE AGREEMENTTransfer and License Agreement • September 10th, 2004 • Barrier Therapeutics Inc • Pharmaceutical preparations • New York
This Amendment No. 1 (the “JPPLP Amendment”) is made and entered into as of September 7, 2004 by and between Janssen Pharmaceutica Products, L.P., a New Jersey limited partnership having a principal place of business at 1123 Trenton-Harbourton Road, Titusville, New Jersey 08628 (hereinafter referred to as “JPPLP”) and Barrier Therapeutics, Inc., a Delaware corporation having an address at 600 College Road East, Suite 3200, Princeton, New Jersey 08540 (hereinafter referred to as “Barrier”).
AMENDMENT NO. 1 TO PLATFORM TECHNOLOGY TRANSFER AND LICENSE AGREEMENTTransfer and License Agreement • March 1st, 2019 • Codexis Inc • Industrial organic chemicals
AMENDMENT NO. 1 TO PLATFORM TECHNOLOGY TRANSFER AND LICENSE AGREEMENT effective as of October 10, 2018 (the EFFECTIVE DATE) (this “Amendment”) by and between CODEXIS, INC., (the “Vendor”), a Delaware corporation, having a place of business at 200 Penobscot Drive, Redwood City, CA 94063 (“CODEXIS”) and MERCK SHARP AND DOHME CORP. (the “Company”), having a place of business at One Merck Drive, Whitehouse Station, NJ 08889-0100. (“MERCK”)
EXHIBIT 10.9 INTELLECTUAL PROPERTY TRANSFER AND LICENSE AGREEMENTTransfer and License Agreement • January 20th, 1999 • Arch Chemicals Inc • Chemicals & allied products • Connecticut
Transfer and License AgreementTransfer and License Agreement • May 3rd, 2019
INTRODUCTIONTransfer and License Agreement • August 14th, 1997 • Millennium Pharmaceuticals Inc • Pharmaceutical preparations • Massachusetts
AMENDMENT TO THE TECHNOLOGY TRANSFER AND LICENSE AGREEMENT BETWEEN CASE WESTERN RESERVE UNIVERSITY AND OSIRIS THERAPEUTICS, INC.Transfer and License Agreement • November 2nd, 2015 • Mesoblast LTD • Biological products, (no disgnostic substances)
This Amendment, effective as of the 18th day of October, 1999, “Amendment Effective Date” between Osiris Therapeutics, Inc. (“OSIRIS”) and Case Western Reserve University (“CWRU”).
FIRST AMENDMENT TO PLATFORM TECHNOLOGY TRANSFER AND LICENSE AGREEMENTTransfer and License Agreement • May 17th, 2019 • Zymeworks Inc. • Pharmaceutical preparations • Delaware
This First Amendment (the “Amendment”) to that certain Platform Technology Transfer and License Agreement, dated April 21, 2016 (the “Agreement”) by and between GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED, a corporation organized and existing under the laws of England and Wales, with its registered office located at 980 Great West Road, Brentford, Middlesex, TW8 9GS, United Kingdom (“GSK”) and ZYMEWORKS INC., a corporation organized and existing under the laws of British Columbia, having an address at 540-1385 West 8th Avenue, Vancouver, BC, Canada V6H 3V9 (“Zymeworks”), is entered into as of May 14, 2019 (the “First Amendment Effective Date”). Zymeworks and GSK are each referred to individually as a “Party” and together as the “Parties.”
PLATFORM TECHNOLOGY TRANSFER AND LICENSE AGREEMENTTransfer and License Agreement • February 28th, 2022 • Codexis, Inc. • Industrial organic chemicals • New York
THIS PLATFORM TECHNOLOGY TRANSFER AND LICENSE AGREEMENT (together with any exhibits attached hereto, this “Agreement”) is made and entered into as of August 3, 2015 (the “Effective Date”), by and between Codexis, Inc., a corporation organized and existing under the laws of Delaware (“Codexis”), and Merck Sharp & Dohme Corp., a corporation organized and existing under the laws of New Jersey (“Merck”). Codexis and Merck are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
ContractTransfer and License Agreement • May 5th, 2020 • Delaware
EX-10.129 9 a2013q2ex10-129.htm EXHIBIT 10.129 EXHIBIT 10.129 [***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT MICRON / NTC CONFIDENTIAL THIRD AMENDED AND RESTATED TECHNOLOGY TRANSFER AND LICENSE AGREEMENT This THIRD AMENDED AND RESTATED TECHNOLOGY TRANSFER AND LICENSE AGREEMENT (this “Agreement”), is made and entered into as of this 17th day of January, 2013, by and between Micron Technology, Inc, a Delaware corporation (“Micron”), and Nanya Technology Corporation (Nanya Technology Corporation [Translation from Chinese]), a company incorporated under the laws of the Republic of China (“NTC”). (Micron and NTC are referred to in this Agreement individually as a “Party” and collectively as the “Parties”). RECITALS A. Micron currently designs and manufactures Stack DRAM Products (as defined herein) and develops Process Technology (as defined herein) therefor. Micron previously dev
Amendment 1 to Asset Transfer and License AgreementTransfer and License Agreement • March 13th, 2017 • Avenue Therapeutics, Inc. • Pharmaceutical preparations
This first amendment ("Amendment 1") to the Asset Transfer and License Agreement by and between Revogenex Ireland Limited, an Irish limited company ("Revogenex"), and Fortress Biotech, Inc. (f/k/a Coronado Biosciences, Inc.), a Delaware corporation ("Fortress")
